Blincyto

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
012320152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVE To evaluate the cost-effectiveness of blinatumomab (Blincyto) vs standard of care (SOC) chemotherapy in adults with… (More)
Is this relevant?
Review
2016
Review
2016
© 2016 Harborside Press® Acute lymphoblastic leukemia (ALL) is a rare form of leukemia, with an estimated 6,250 new cases… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
AM J HEALTH-SYST PHARM | VOLUME 73 | NUMBER 2 | JANUARY 15, 2016 19 Minimizing waste during preparation of blinatumomab infusions… (More)
Is this relevant?
Review
2015
Review
2015
  • The Medical letter on drugs and therapeutics
  • 2015
Blinatumomab (Blincyto) was effective in inducing a complete remission in 33% of patients with relapsed or refractory… (More)
Is this relevant?
Review
2015
Review
2015
OBJECTIVE To review the clinical pharmacology, efficacy, and safety of blinatumomab for the treatment of pediatric and adult… (More)
Is this relevant?
Review
2015
Review
2015
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high… (More)
  • figure 1
  • figure 2
Is this relevant?